Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: An exploratory analysis of the TRYPHAENA study

Breast Cancer Research

Volumn 16, Issue 4, 2014, Pages

  Schneeweiss, Andreas ^a   Chia, Stephen ^b   Hegg, Roberto ^c   Tausch, Christoph ^d   Deb, Rahul ^e   Ratnayake, Jayantha ^f   McNally, Virginia ^f   Ross, Graham ^f   Kiermaier, Astrid ^g   Cortés, Javier ^h  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Hospital Perola Byington   (Brazil)

^d Breast Centre Zurich   (Switzerland)

^e DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g Pharma Research and Early Development   (Switzerland)

^h VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIRUBICIN; FLUOROURACIL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR BIOPSY; BREAST NEOPLASMS; CANCER STAGING; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84903806146     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3690     Document Type: Article

References (27)

1. Menard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000, 182:150-162. 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E, 10623878.
2. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368. 10.1634/theoncologist.2008-0230, 19346299.
3. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28:92-98. 10.1200/JCO.2008.19.9844, 2799236, 19933921.
4. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology. Breast cancer. Version 2.2013. [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp], National Comprehensive Cancer Network.
5. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274. 10.1200/JCO.2005.04.173, 15911866.
6. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, . CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119. 10.1056/NEJMoa1113216, 22149875, CLEOPATRA Study Group.
7. Swain S, Kim S, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes M, Baselga J. Confirmatory overall survival analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive first-line MBC. Cancer Res 2012, 72:P5-18-26. At SABCS 2012, San Antonio, Texas.
8. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440. 10.1016/j.ccr.2009.03.020, 19411071.
9. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328. 10.1016/S1535-6108(04)00083-2, 15093539.
10. Gianni L, Bianchini G, Kiermaier A, Bianchi G, Im Y, Pienkowski T, Roman L, Liu M, Tseng L, Ratnayake J, Szado T, Ross G, Valagussa P. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2012, 71:S5-1. At SABCS 2011, San Antonio, Texas.
11. Baselga J, Corte´s J, Im S-A. Biomarker analyses in CLEOPATRA: A Phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012, 71:S5-1. At SABCS 2012, San Antonio, Texas.
12. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
13. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22:2812-2822. 10.1038/sj.onc.1206388, 12743604.
14. Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94:247-252. 10.1038/sj.bjc.6602926, 2361109, 16404430.
15. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1:707-717.
16. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, Garcia-Conde J, Baselga J, Clinton GM. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006, 12:424-431. 10.1158/1078-0432.CCR-05-1807, 16428482.
17. Kim C, Bryant J, Horne Z, Geyer CE, Wickerham DL, Wolmark N, Paik S. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggest pro-apoptotic function of dysregulated cMYC in vivo [abstract]. Breast Cancer Res Treat 2005, 94:S6.
18. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001, 93:1852-1857. 10.1093/jnci/93.24.1852, 11752009.
19. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005, 16:234-239. 10.1093/annonc/mdi059, 15668276.
20. Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B. The utility of serum HER2 extracellular domain (ECD) assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009, 27:1685-1693. 10.1200/JCO.2008.16.8351, 19255335.
21. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortes J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013, 24:2278-2284. 10.1093/annonc/mdt182, 23704196.
22. Schneeweiss A, Hegg R, Tausch C, Deb R, Ratnayake J, Kiermaier A, McNally V, Ross G, Cortes J. Biomarker (BM) analyses of a Phase II study of neoadjuvant pertuzumab and trastuzumab with and without anthracycline (ATC)-containing chemotherapy for treatment of HER2-positive early breast cancer (BC) (TRYPHAENA). Annals Oncol 2012, 23:ix73-ix94. At ESMO 2012, Vienna, Austria.
23. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807. 10.1200/JCO.2003.11.069, 12953099.
24. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011, 29:859-867. 10.1200/JCO.2009.27.5644, 3068060, 21189395.
25. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804. 10.1200/JCO.2011.38.8595, 22508812.
26. Gianni L, Bianchini G, Valagussa P, Belousov A, Thomas M, Ross G, Pusztai L. Adaptive immune system and immune checkpoints are associated with response to pertuzumab and trastuzumab in the NeoSphere study. Cancer Res 2012, 72:S6-S7. At SABCS 2012, San Antonio, Texas.
27. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, . NeoALTTO Study Team Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640. 10.1016/S0140-6736(11)61847-3, 22257673, NeoALTTO Study Team.